BMS Opts In On Exscientia’s AI-Designed Immune-Modulating Candidate

Bristol Myers Squibb Will Handle Compound’s Clinical, Commercial Development

Bristol Myers Squibb will in-license an immune-modulating drug candidate created by AI-pioneer Exscientia, the first in their expanded multi-target alliance announced in May.

AI-designed drug is first in duo's multi-target collaboration to reach in-license milestone • Source: Alamy

AI pioneer Exscientia Ltd. has generated the first novel drug candidate in its $1.2bn partnership with Bristol Myers Squibb Company– that being an immune-modulating compound, for which the nine-year-old spinout drug discovery group will get $20m from BMS for the early exploration work.

The in-licensed candidate targets a critical immunological kinase that has “historically proven difficult to target” due to the need for...

More from Business

More from Scrip

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By 

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.

Gateway To Africa: Natco Bids For 35.75% Of Adcock Ingram

 

Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through, it will result in the delisting of Adcock, with Bidvest and Natco co-owning the firm.